Boston Scientific CORP Form 4 insider transactions

Boston Scientific Corporation announced a definitive agreement to acquire Penumbra, Inc., a leader in mechanical thrombectomy and neurovascular therapies, on January 15, 2026.

Boston Scientific Corporation announced an agreement to acquire Penumbra, a medical technology company specializing in neurovascular and mechanical thrombectomy, for $15 billion in cash and stock.

Boston Scientific Corporation announced a definitive agreement to acquire Penumbra, Inc. through a merger, offering Penumbra shareholders a choice of cash or Boston Scientific common stock.

Boston Scientific announced a definitive agreement to acquire Penumbra, Inc. for approximately $14.5 billion, expanding its cardiovascular and neurovascular portfolios.

Boston Scientific's EVP Arthur C. Butcher sold 17,313 shares of common stock for over $101 per share after exercising options, all under a pre-established 10b5-1 trading plan.

Miriam O'Sullivan, SVP and Chief HR Officer at Boston Scientific, reported a gift of 260 common shares.

Boston Scientific's EVP & Group President of Cardiology, Joseph Michael Fitzgerald, reported gifting 10,300 shares of common stock in November 2025.

Boston Scientific Director Ellen M. Zane sold 12,891 shares of common stock for $98.2839 per share under a pre-established trading plan.

Joseph Michael Fitzgerald, EVP & Group President of Cardiology at Boston Scientific, exercised options and subsequently sold a portion of his common stock holdings.

Boston Scientific CEO Michael F. Mahoney's associated trusts completed gift transactions of common stock, resulting in changes to his indirect beneficial ownership.

Boston Scientific director Ellen M. Zane's previously reported sale of 12,891 shares was rescinded due to a broker error, restoring her beneficial ownership.

Boston Scientific Director Ellen M. Zane sold a total of 12,891 shares of common stock across two transactions in late October 2025, pursuant to a pre-established 10b5-1 trading plan.

Joseph Michael Fitzgerald, EVP & Group President of Cardiology at Boston Scientific, sold 50,000 shares of common stock for over $98 per share after exercising options at $26.15, pursuant to a Rule 10b5-1 plan.

Boston Scientific's EVP & Group President of Cardiology, Joseph Michael Fitzgerald, exercised stock options and subsequently sold a portion of his common stock holdings.

Boston Scientific's EVP and CFO, Jonathan Monson, reported the acquisition of common stock from RSU vesting and subsequent disposition for tax obligations.

Boston Scientific Director Edward J. Ludwig gifted 500 shares of common stock, reducing his direct beneficial ownership to 17,979 shares.

Boston Scientific EVP Joseph Fitzgerald exercised 50,000 stock options and sold the resulting shares for a significant profit under a pre-established trading plan.

Arthur Butcher, EVP at Boston Scientific, exercised stock options and sold 17,313 shares of common stock on August 1, 2025, per a pre-established 10b5-1 trading plan.

Boston Scientific Director Yoshiaki Fujimori reported the sale of 2,901 shares of common stock at $106.99 per share, reducing his direct beneficial ownership to 2,081 shares, as part of a Rule 10b5-1 pre-planned transaction scheduled for July 29, 2025.

Boston Scientific Director Edward J. Ludwig sold 4,000 shares of common stock for over $106 per share in a pre-planned transaction.

Boston Scientific's Executive Vice President and Chief Financial Officer, Jonathan Monson, was granted 8,350 Restricted Stock Units and options to purchase 22,173 shares of common stock, effective July 1, 2025, as part of his compensation package.

Joseph Michael Fitzgerald, EVP & Group President of Cardiology at Boston Scientific, exercised stock options and subsequently sold 50,000 shares of common stock on July 1, 2025, as part of a pre-established Rule 10b5-1 trading plan.

Vance R. Brown, SVP, GC and Corporate Secretary of Boston Scientific Corp., reported the acquisition of 4,036 shares of common stock through RSU vesting and the disposition of 1,952 shares for tax withholding.

Joseph Michael Fitzgerald, EVP & Group President of Cardiology at Boston Scientific Corp, exercised stock options and sold 56,372 shares of common stock for over $102 per share under a Rule 10b5-1 trading plan.

Boston Scientific's Chairman, President, and CEO, Michael F. Mahoney, exercised stock options and subsequently sold a significant number of shares on June 2, 2025, as part of a pre-established Rule 10b5-1 trading plan.

Edward J. Ludwig, a Director at Boston Scientific Corp (BSX), sold 4,000 shares of common stock for approximately $418,367 under a Rule 10b5-1 trading plan.

Vance R. Brown, SVP, GC and Corp. Secretary of Boston Scientific, reports the sale of 4,826 shares of common stock at a price of $106.42 on May 21, 2025, under a pre-established Rule 10b5-1 trading plan.

Director Ellen M. Zane acquired 2,081 shares of Boston Scientific common stock through an annual equity award.

Director David S. Wichmann of Boston Scientific Corp. received an annual equity award in the form of restricted stock.

Director John E. Sununu received an annual equity award of 2,081 shares of Boston Scientific common stock on May 8, 2025.